Praxis: Priced For Perfection Heading Into 2026 [Seeking Alpha]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Seeking Alpha
Ulixacaltamide's Essential3 data appear statistically robust, but a 27% drug-related discontinuation rate raises real-world persistence and regulatory risk concerns. Recent Breakthrough Therapy Designation for ulixacaltamide and positive epilepsy data clarify regulatory paths, making PRAX a multi-NDA platform by 2026. PRAX's $7.62B valuation bakes in blockbuster assumptions; risk/reward is less compelling until commercial and regulatory clarity emerges. J Studios/DigitalVision via Getty Images Introduction Stock of Praxis Precision Medicines ( PRAX ) has continued north following Phase 3 data for its essential tremor, or ET, drug candidate, ulixacaltamide. My last look at the neurology disease-focused biotech followed positive Essential3 This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical StrategyGlobeNewswire
- Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $83.00 to $95.00. They now have an "underperform" rating on the stock.MarketBeat
- Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress [Yahoo! Finance]Yahoo! Finance
PRAX
Earnings
- 11/5/25 - Beat
PRAX
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- PRAX's page on the SEC website